

REFERÈNCIES

**Adams B**, Holte S, Randolph T, Banks HT. STI control of HIV infection. 1<sup>st</sup> SIAM Conference on the Life Sciences. Boston, USA. March 2002.

**Alcami J**, Lain de Lera T, Folgueira L, Pedraza MA, Jacque JM, Bachelerie F, Noriega AR, Hay RT, Harrich D, Gaynor RB, et al.

Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. *EMBO J*. 1995 Apr 3;14(7):1552-60.

**Altfield M**, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, and al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. *J Exp Med* 2001, 15; 193(2): 169-80.

**Allain JP**, Laurian Y, Paul DA, Senn D.

Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs.

*Lancet*. 1986 Nov 29;2(8518):1233-6.

**Allain JP**, Frommel D, Bosser C, Gazengel C, Larrieu MJ, Sultan Y.

The role of HIV infectivity and composition of factor VIII concentrates on the immunity of haemophiliacs positive for HIV antibodies.

*Vox Sang*. 1987;53(1):37-43.

**Asjo B**, Morfeldt-Manson L, Albert J, Biberfeld G, Karlsson A, Lidman K, Fenyo EM.

Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection.

*Lancet*. 1986 Sep 20;2(8508):660-2.

**Autran B**, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J.

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

*Science*. 1997 Jul 4;277(5322):112-6.

**Autran B**, Carcelain G.

AIDS. Boosting immunity to HIV--can the virus help?

*Science*. 2000 Nov 3;290(5493):946-9.

**Baxter JD**, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Bein Community Programs for Clinical Research on AIDS. *AIDS*. 2000;14:F83-F93.

**Baggioni M**, Dewald B, Moser B. Interleukin 8 and related chemotactic cytokines CXC and CC chemokines. *Adv Immunol* 1994; 55:97-179.

**Barre-Sinoussi F**, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for

acquired immune deficiency syndrome (AIDS).  
*Science*. 1983 May 20;220(4599):868-71.

**Berger EA**, Murphy PM, Farber JM.  
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. *Annu Rev Immunol*. 1999;17:657-700

**Betts MR**, Krowka JF, Kepler TB, Davidian M, Christopherson C, Kwok S, Louie L, Eron J, Sheppard H, Frelinger JA.  
Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. *AIDS Res Hum Retroviruses*. 1999 Sep 1;15(13):1219-28.

**Binley JM**, Schiller DS, Ortiz GM, Hurley A, Nixon DF, Markowitz MM, Moore JP.  
The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy.  
*J Infect Dis*. 2000 Apr;181(4):1249-63. Epub 2000 Apr 13.

**Blankson JN**, Persaud D, Siliciano RF.  
The challenge of viral reservoirs in HIV-1 infection.  
*Annu Rev Med*. 2002;53:557-93

**Bleul CC**, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA.  
The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. *Nature*. 1996 Aug 29;382(6594):829-33.

**Boden D**, Hurley A, Zhan L, et al. HIV-1 drug resistance in newly infected individuals.  
*J Am Med Association* 1999; 282:1135-1141

**Bofill M**, Gombert W, Borthwick NJ, Akbar AN, McLaughlin JE, Lee CA, Johnson MA, Pinching AJ, Janossy G. Presence of CD3+CD8+Bcl-2(low) lymphocytes undergoing apoptosis and activated macrophages in lymph nodes of HIV-1+ patients. *Am J Pathol*. 1995 Jun;146(6):1542-55.

**Bollinger RC Jr**, Kline RL, Francis HL, Moss MW, Bartlett JG, Quinn TC.  
Acid dissociation increases the sensitivity of p24 antigen detection for the evaluation of antiviral therapy and disease progression in asymptomatic human immunodeficiency virus-infected persons. *J Infect Dis*. 1992 May;165(5):913-6.

**Bonhoeffer S**, Remiszewski M, Ortiz GM, Nixon DF.  
Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. *AIDS*. 2000 Oct 20;14(15):2313-22.

**Boucher CA**, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 HIV-positive subjects. *J Infect Dis* 1992; 165:105-110

**Boucher CA**, Keulen W, van Bommel T, Nijhuis M, de Jong D, de Jong MD, Schipper P, Back NK Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. *Antimicrob Agents Chemother* 1996 Oct;40(10):2404-9.

- Boulmé R**, Halfon P, Diaz R, et al. Comparative evaluation between five automated resistance interpretation algorithms. *Antiviral Ther* 2001; 6(suppl 1):121
- Bouscarat F**, Levacher M, Dazza MC, Chau F, Desforges B, Muffat-Joly M, Matheron S, Girard PM, Sinet M.  
Prospective study of CD8+ lymphocyte activation in relation to viral load in HIV-infected patients with > or = 400 CD4+ lymphocytes per microliter. *AIDS Res Hum Retroviruses*. 1999 Nov 1;15(16):1419-25.
- Briones C**, Rodríguez C, Del Romero J, et al. Primary genotypic and phenotypic resistance to antiretroviral drugs in recent seroconverters in Madrid. *J Acquir Immune Defic Syndr* 2001; 26:145-150
- Brew BJ**, Bhalla RB, Paul M, Gallardo H, McArthur JC, Schwartz MK, Price RW. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. *Ann Neurol*. 1990 Oct;28(4):556-60.
- Brunet M**, Oppenheimer F, Martorell J, Vilardell J, Carreno MC, Carrillo M, Corbella J. Mycophenolic acid monitoring: evaluation of the EMIT MPA immunoassay in kidney and lung transplantation. *Transplant Proc*. 1999 Sep;31(6):2275-6.
- Brunet M**, Martorell J, Oppenheimer F, Vilardell J, Millan O, Carrillo M, Rojo I, Corbella J. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. *Transpl Int*. 2000;13 Suppl 1:S301-5.
- Bubrinisky MI**, Stanwick L, Demsey MP, et al. Quiescent T Lymphocytes as an inducible virus reservoir of HIV-1 infection. *Science* 1991; 254: 423-7.
- Buchbinder SP**, Katz MH, Hessel NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. *AIDS*. 1994 Aug;8(8):1123-8.
- Buchbinder S**, Vittinghoff E.  
HIV-infected long-term nonprogressors: epidemiology, mechanisms of delayed progression, and clinical and research implications. *Microbes Infect*. 1999 Nov;1(13):1113-20.
- Busch MP**, Operskalski EA, Mosley JW, Lee TH, Henrard D, Herman S, Sachs DH, Harris M, Huang W, Stram DO.  
Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. Transfusion Safety Study Group. *J Infect Dis*. 1996 Jul;174(1):26-33.
- Bushman F**.  
Measuring covert HIV replication during HAART: the abundance of 2-LTR circles is not a reliable marker. *AIDS*. 2003 Mar 28;17(5):749-50.
- Butto S**, Argentini C, Mazzella AM, Iannotti MP, Leone P, Leone P, Nicolosi A, Rezza G. Dual infection with different strains of the same HIV-1 subtype. *AIDS*. 1997 Apr;11(5):694-6.

- Cabana M**, Clotet B, Martinez MA.  
Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors.  
J Med Virol. 1999 Dec;59(4):480-90.
- Cann AJ**, Karn J.  
Molecular biology of HIV: new insights into the virus life-cycle.  
AIDS. 1989;3 Suppl 1:S19-34. Review.
- Cao J**, McNevin J, Malhotra U, McElrath MJ. Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection. J Immunol. 2003 Oct 1;171(7):3837-46.
- Cao YZ**, Valentine F, Hojvat S, Allain JP, Rubinstein P, Mirabile M, Czelusniak S, Leuther M, Baker L, Friedman-Kien AE.  
Detection of HIV antigen and specific antibodies to HIV core and envelope proteins in sera of patients with HIV infection. Blood. 1987 Aug;70(2):575-8.
- Carcelain G**, Tubiana R, Samri A, Calvez V, Delaugerre C, Agut H, Katlama C, Autran B.  
Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol. 2001 Jan;75(1):234-41.
- Carpenter CC**, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA.  
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996 Jul 10;276(2):146-54.
- Carpenter CC**, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA.  
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997 Jun 25;277(24):1962-9.
- Carpenter CC**, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA.  
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000 Jan 19;283(3):381-90.
- Carrillo A**, Ratner L.  
Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells.  
J Virol. 1996 Feb;70(2):1310-6.
- Cavert W**, Notermans DW, Staskus K, Wietgreffe SW, Zupancic M, Gebhard K, Henry K, Zhang ZQ, Mills R, McDade H, Schuirth CM, Goudsmit J, Danner SA, Haase AT.

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. *Science*. 1997 May 9;276(5314):960-4.

**Chaisson RE**, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, Smith T, Craft JC, Sattler FR.

Clarithromycin therapy for bacteremic *Mycobacterium avium* complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. *Ann Intern Med*. 1994 Dec 15;121(12):905-11.

**Chan DC**, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. *Proc Natl Acad Sci U S A*. 1998 Dec 22;95(26):15613-7.

**Chapuis AG**, Paolo Rizzardi G, D'Agostino C, Attinger A, Knabenhans C, Fleury S, Acha-Orbea H, Pantaleo G.

Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. *Nat Med*. 2000 Jul;6(7):762-8.

**Cheng-Mayer C**, Seto D, Tateno M, Levy JA.

Biologic features of HIV-1 that correlate with virulence in the host. *Science*. 1988 Apr 1;240(4848):80-2.

**Cheng-Mayer C**, Weiss C, Seto D, Levy JA.

Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus. *Proc Natl Acad Sci U S A*. 1989 Nov;86(21):8575-9.

**Chen Y**, Rinaldo C, Gupta P.

A semiquantitative assay for CD8+ T-cell-mediated suppression of human immunodeficiency virus type 1 infection. *Clin Diagn Lab Immunol*. 1997 Jan;4(1):4-10.

**Cheingsong-Popov R**, Callow D, Beddows S, Shaunak S, Wasi C, Kaleebu P, Gilks C, Petrascu IV, Garaev MM, Watts DM, et al.

Geographic diversity of human immunodeficiency virus type 1: serologic reactivity to env epitopes and relationship to neutralization. *J Infect Dis*. 1992 Feb;165(2):256-61.

**Chesebro B**, Wehrly K, Nishio J, Perryman S.

Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. *J Virol*. 1996 Dec;70(12):9055-9.

**Chesney MA**, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW.

Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). *AIDS Care*. 2000 Jun;12(3):255-66.

**Chess Q**, Daniels J, North E, Macris NT.

Serum immunoglobulin elevations in the acquired immunodeficiency syndrome (AIDS): IgG, IgA, IgM, and IgD. *Diagn Immunol*. 1984;2(3):148-53.

- Choe H**, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. *Cell*. 1996 Jun 28;85(7):1135-48.
- Chun TW**, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. *Nat Med*. 1995 Dec;1(12):1284-90.
- Chun TW**, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. *Proc Natl Acad Sci U S A*. 1997 Nov 25;94(24):13193-7.
- Chun TW**, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. *Proc Natl Acad Sci U S A*. 1998 Jul 21;95(15):8869-73.
- Chun TW**, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, Davey RT Jr, Dybul M, Kovacs JA, Metcalf JA, Mican JM, Berrey MM, Corey L, Lane HC, Fauci AS. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. *Nat Med*. 1999 Jun;5(6):651-5.
- Chun TW**, Davey RT Jr, Ostrowski M, Shawn Justement J, Engel D, Mullins JL, Fauci AS. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. *Nat Med*. 2000 Jul;6(7):757-61.
- Clark SJ**, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, Kappes JC, Hahn BH, Shaw GM. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. *N Engl J Med*. 1991 Apr 4;324(14):954-60.
- Clark RA**, Brandon W, Dumestre J, Pindaro C. Clinical manifestations of infection with the human immunodeficiency virus in women in Louisiana. *Clin Infect Dis*. 1993 Aug;17(2):165-72.
- Clarke DK**, Duarte EA, Elena SF, Moya A, Domingo E, Holland J. The red queen reigns in the kingdom of RNA viruses. *Proc Natl Acad Sci U S A*. 1994 May 24;91(11):4821-4.
- Clavel F**, Brun-Vezinet F, Guetard D, Chamaret S, Laurent A, Rouzioux C, Rey M, Katlama C, Rey F, Champelinaud JL, et al. LAV type II: a second retrovirus associated with AIDS in West Africa. *C R Acad Sci III*. 1986;302(13):485-8. French.
- Coffin JM**. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. *Science*. 1995 Jan 27;267(5197):483-9.

**Cohen OJ**, Vaccarezza M, Lam GK, Baird BF, Wildt K, Murphy PM, Zimmerman PA, Nutman TB, Fox CH, Hoover S, Adelsberger J, Baseler M, Arthos J, Davey RT Jr, Dewar RL, Metcalf J, Schwartzenruber DJ, Orenstein JM, Buchbinder S, Saah AJ, Detels R, Phair J, Rinaldo C, Margolick JB, Fauci AS, et al.

Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors. *J Clin Invest.* 1997 Sep 15;100(6):1581-9.

**Cohen C**, Kessler H, Hunt S, et al. Phenotypic resistance testing significantly improves response to therapy: final analysis of a randomized trial (VIRA3001 ). *Antivir Ther.* 2000;5(suppl 3):67.

**Cohen DE**, Walker BD.

Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection. *Clin Infect Dis.* 2001 Jun 15;32(12):1756-68. Epub 2001 May 16.

**Condra JH**, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, et al.

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. *Nature.* 1995 Apr 6;374(6522):569-71.

**Condra JH**, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, Laird D, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Yang T, Chodakewitz JA, Deutsch PJ, Leavitt RY, Massari FE, Mellors JW, Squires KE, Steigbigel RT, Tepler H, Emmini EA.

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. *J Virol.* 1996 Dec;70(12):8270-6.

**Connor RI**, Mohri H, Cao Y, Ho DD.

Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. *J Virol.* 1993 Apr;67(4):1772-7.

**Connor RI**, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. *J Exp Med.* 1997 Feb 17;185(4):621-8.

**Coombs RW**, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumpacker CS, Kahn J.

Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. *J Infect Dis.* 1996 Oct;174(4):704-12.

**Cullen BR**, Garrett ED.

A comparison of regulatory features in primate lentiviruses. *AIDS Res Hum Retroviruses.* 1992 Mar;8(3):387-93. Review.

**Cullen BR**

HIV-1 auxiliary proteins: making connections in a dying cell. *Cell*. 1998 May 29;93(5):685-92. Review.

**Daar ES**, Moudgil T, Meyer RD, Ho DD.

Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. *N Engl J Med*. 1991 Apr 4;324(14):961-4.

**D'Aquila RT**, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, et al.

Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. *Ann Intern Med*. 1995 Mar 15;122(6):401-8.

**Dean M**, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien SJ.

Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the *CKR5* structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. *Science*. 1996 Sep 27;273(5283):1856-62.

**de Jong MD**, de Boer RJ, de Wolf F, Foudraine NA, Boucher CA, Goudsmit J, Lange JM.

Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. *AIDS*. 1997 Sep;11(11):F79-84.

**de Santis C**, Lopalco L, Robbioni P, Longhi R, Rappocciolo G, Siccardi AG, Beretta A.

Human antibodies to immunodominant C5 region of HIV-1 gp120 cross-react with HLA class I on activated cells. *AIDS Res Hum Retroviruses*. 1994 Feb;10(2):157-62.

**Deeks SG**, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM.

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. *N Engl J Med*. 2001 Feb 15;344(7):472-80.

**Deeks SG**, Barditch-Crovo P, Collier A, Smith A, Miller M, McGowan I, Coakley DF. Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate. *J Acquir Immune Defic Syndr*. 2001 Dec 1;28(4):336-9.**DeGruttola V**, Beckett LA, Coombs RW, Arduino JM, Balfour HH Jr, Rasheed S, Hollinger FB, Fischl MA, Volberding P.

Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. *Aids Clinical Trials Group Virology Laboratories*. *J Infect Dis*. 1994 Apr;169(4):713-21.

**Delassus S**, Cheynier R, Wain-Hobson S.

Nonhomogeneous distribution of human immunodeficiency virus type 1 proviruses in the spleen. *J Virol*. 1992 Sep;66(9):5642-5.



**Delwart EL**

Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. *J Virol.* 1994 Oct;68(10):6672-83.

**Delwart EL**, Gordon CJ.

Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. *Methods.* 1997 Aug;12(4):348-54.

**Delwart EL**, Pan H, Neumann A, Markowitz M.

Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance. *J Virol.* 1998 Mar;72(3):2416-21.

**Demeter LM**, Meehan PM, Morse G, Fischl MA, Para M, Powderly W, Leedom J, Holden-Wiltse J, Greisberger C, Wood K, Timpone J Jr, Wathen LK, Nevin T, Resnick L, Batts DH, Reichman RC. Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1998 Oct 1;19(2):135-44.

**Deng H**, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. *Nature.* 1996 Jun 20;381(6584):661-6.

**Derdeyn CA**, Decker JM, Sfakianos JN, Zhang Z, O'Brien WA, Ratner L, Shaw GM, Hunter E. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. *J Virol.* 2001 Sep;75(18):8605-14.

**Descamps D**, Flandre P, calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. *JAMA* 2000; 283:205-211

**Devereux HL**, Youle M, Johnson MA, Loveday C.

Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. *AIDS.* 1999 Dec 24;13(18):F123-7.

**Domingo E**, Menendez-Arias L, Quinones-Mateu ME, Holguin A, Gutierrez-Rivas M, Martinez MA, Quer J, Novella IS, Holland JJ.

Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. *Prog Drug Res.* 1997;48:99-128.

**Domingo E**, Mas A, Yuste E, Pariente N, Sierra S, Gutierrez-Riva M, Menendez-Arias L. Virus population dynamics, fitness variations and the control of viral disease: an update. *Prog Drug Res.* 2001;57:77-115.

**Doranz BJ**, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW.

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. *Cell.* 1996 Jun 28;85(7):1149-58.

- Dorman KS**, Kaplan AH, Lange K, Sinsheimer JS.  
Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1?  
*J Acquir Immune Defic Syndr*. 2000 Dec 15;25(5):398-402.
- Dorrucchi M**, Rezza G, Vlahov D, Pezzotti P, Sinicco A, Nicolosi A, Lazzarin A, Galai N, Gafa S, Pristera R, et al.  
Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. Italian Seroconversion Study.  
*AIDS*. 1995 Jun;9(6):597-604.
- Doyon L**, Croteau G, Thibeault D, et al. Second locus involved in HIV type 1 resistance to protease inhibitors. *J Virol* 1996; 70:3763-3769
- Dragic T**, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA.  
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.  
*Nature*. 1996 Jun 20;381(6584):667-73.
- Drake RR**, Neamati N, Hong H, Pilon AA, Sunthankar P, Hume SD, Milne GW, Pommier Y.  
Identification of a nucleotide binding site in HIV-1 integrase.  
*Proc Natl Acad Sci U S A*. 1998 Apr 14;95(8):4170-5.
- Drew WL**, Anderson R, Lang W, Miner RC, Davis G, Lalezari J.  
Failure of high-dose oral acyclovir to suppress CMV viremia or induce ganciclovir-resistant CMV in HIV antibody positive patients.  
*J Acquir Immune Defic Syndr Hum Retrovirol*. 1995 Mar 1;8(3):289-91.
- Durant J**, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. *Lancet*. 1999;353:2195-2199.
- Dybul M**, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K, Larder B, Dewar RL, Fox CH, Hallahan CW, Justement JS, Migueles SA, Metcalf JA, Davey RT, Daucher M, Pandya P, Baseler M, Ward DJ, Fauci AS.  
Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.  
*Proc Natl Acad Sci U S A*. 2001 Dec 18;98(26):15161-6. Epub 2001 Dec 04.
- Dybul M**, Daucher M, Jensen MA, Hallahan CW, Chun TW, Belson M, Hidalgo B, Nickle DC, Yoder C, Metcalf JA, Davey RT, Ehler L, Kress-Rock D, Nies-Kraske E, Liu S, Mullins JI, Fauci AS.  
Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy.  
*J Virol*. 2003 Mar;77(5):3229-37.
- Escarmis C**, Davila M, Charpentier N, Bracho A, Moya A, Domingo E.  
Genetic lesions associated with Muller's ratchet in an RNA virus.  
*J Mol Biol*. 1996 Nov 29;264(2):255-67.

**Fagard C**, Oxenius A, Gunthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B; Swiss HIV Cohort Study. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. *Arch Intern Med.* 2003 May 26;163(10):1220-6.

**Feng Y**, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science.* 1996 May 10;272(5263):872-7.

**Finzi D**, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science.* 1997 Nov 14;278(5341):1295-300.

**Finzi D**, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. *Nat Med.* 1999 May;5(5):512-7.

**Foli A**, Maserati R, Minoli L, Wainberg MA, Gallo RC, Lisziewicz J, Lori F. Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine. *AIDS.* 1998 Jun 18;12(9):1113-4.

**Folks TM**, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. *Proc Natl Acad Sci U S A.* 1989 Apr;86(7):2365-8.

**Font E**, Rosario O, Santana J, et al. Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from HIV-infected individuals by tandem mass spectrometry. *Antimicrob Agents Chemother* 1999; 12:2964-2968

**Furtado MR**, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. *N Engl J Med.* 1999 May 27;340(21):1614-22

**Easterbrook PJ.** Non-progression in HIV infection. *AIDS.* 1994 Aug;8(8):1179-82.

**Echaniz P**, Arrizabalaga J, Iribarren JA, Cuadrado E. CD8+CD38+ and CD8+DR+ peripheral blood lymphoid subsets of HIV-infected intravenous drug abusers correlate with CD4+ cell counts and proliferation to mitogens. *Cell Immunol.* 1993 Aug;150(1):72-80.

**Embretson J**, Zupancic M, Beneke J, Till M, Wolinsky S, Ribas JL, Burke A, Haase AT.

Analysis of human immunodeficiency virus-infected tissues by amplification and in situ hybridization reveals latent and permissive infections at single-cell resolution. *Proc Natl Acad Sci U S A*. 1993 Jan 1;90(1):357-61.

**Emermam M**, Malin MH. HIV-1 regulatory/accessory genes: keys to unravelling viral and host cell biology. *Science*. 1998; 280: 1880-4.

**Engelstad M.**

Genetic diversity of env V3 loop sequences in HIV type 1-infected homosexuals, heterosexuals, intravenous drug users, and hemophilia patients in Norway: high prevalence of subtype B and detection of subtype C. *AIDS Res Hum Retroviruses*. 1996 Dec 10;12(18):1733-8.

**Escaich S**, Ritter J, Rougier P, Bizollon T, Lepot D, Lamelin JP, Sepetjan M, Trepo C

HIV detection in culture of peripheral blood mononuclear cells: a relevant in vitro correlate of the antiviral effect of ZDV in vivo. *J Acquir Immune Defic Syndr*. 1992;5(8):829-34.

**Fagard C**, Oxenius A, Gunthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B; Swiss HIV Cohort Study.

A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. *Arch Intern Med*. 2003 May 26;163(10):1220-6.

**Fahy JL**, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV.

The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. *N Engl J Med*. 1990 Jan 18;322(3):166-72.

**Fauci AS.**

Optimal immunity to HIV--natural infection, vaccination, or both?

*N Engl J Med*. 1991 Jun 13;324(24):1733-5.

**Feinberg MB**, Jarrett RF, Aldovini A, Gallo RC, Wong-Staal F. HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA. *Cell*. 1986 Sep 12;46(6):807-17.

**Feng Y**, Broder CC, Kennedy PE, Berger EA.

HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science*. 1996 May 10;272(5263):872-7.

**Fenouillet E**, Blanes N, Coutellier A, Demarquest J, Rozenbaum W, Gluckman JC.

[Predictive value of the assay of serum anti-p25 antibodies in patients with human immunodeficiency virus (HIV-1) infection]. *Ann Med Interne (Paris)*. 1993;144(5):329-34.

**Fenyo EM**, Morfeldt-Manson L, Chiodi F, Lind B, von Gegerfelt A, Albert J, Olausson E, Asjo B.

Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. *J Virol.* 1988 Nov;62(11):4414-9.

**Finkel TH**, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM, Kupfer A.

Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. *Nat Med.* 1995 Feb;1(2):129-34

**Finzi D**, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF.

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science.* 1997 Nov 14;278(5341):1295-300.

**Finzi D**, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF.

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. *Nat Med.* 1999 May;5(5):512-7.

**Frade JM**, Llorente M, Mellado M, Alcamí J, Gutierrez-Ramos JC, Zaballos A, Real G, Martínez-A C.

The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection. *J Clin Invest.* 1997 Aug 1;100(3):497-502.

**Frost SD.**

Dynamics and evolution of HIV-1 during structured treatment interruptions. *AIDS Rev.* 2002 Jul-Sep;4(3):119-27.

**Fuchs D**, Unterweger B, Hausen A, Reibnegger G, Werner ER, Hengster P, Hinterhuber H, Dierich MP, Wachter H, Blattner WA, et al.

Anti-HIV-1 antibodies, anti-HTLV-I antibodies and neopterin levels in parenteral drug addicts in the Austrian Tyrol. *J Acquir Immune Defic Syndr.* 1988;1(1):65-6.

**Furtado MR**, Kingsley LA, Wolinsky SM.

Changes in the viral mRNA expression pattern correlate with a rapid rate of CD4+ T-cell number decline in human immunodeficiency virus type 1-infected individuals. *J Virol.* 1995 Apr;69(4):2092-2100.

**Furtado MR**, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM.

Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. *N Engl J Med.* 1999 May 27;340(21):1614-22.

**Gaines H**, von Sydow M, Sonnerborg A, Albert J, Czajkowski J, Pehrson PO, Chiodi F, Moberg L, Fenyo EM, Asjo B, et al.

Antibody response in primary human immunodeficiency virus infection. *Lancet.* 1987 May 30;1(8544):1249-53.

**Gallaher WR**, Ball JM, Garry RF, Griffin MC, Montelaro RC. A general model for the transmembrane proteins of HIV and other retroviruses. *AIDS Res Hum Retroviruses*. 1989 Aug;5(4):431-40.

**Ganeshan S**, Dickover RE, Korber BT, Bryson YJ, Wolinsky SM. Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease. *J Virol*. 1997 Jan;71(1):663-77.

**Garcia F**, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miro JM, Gatell JM. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. *AIDS*. 1999 Dec 3;13(17):2377-88.

**Garcia F**, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miro JM, Gatell JM. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. *Early Anti-Retroviral Therapy Study*. *J Acquir Immune Defic Syndr*. 2000 Sep 1;25(1):26-35.

**Gatell JM**, Podzamczer D, Clotet B, Ocana I, Estany C, Figuerola M, Mariscal D. [Incidence of infection with human immunodeficiency virus and acquired immunodeficiency syndrome in a population from the Barcelona area] *Med Clin (Barc)*. 1988 Nov 26;91(18):681-4.

**Gatell JM**, Blanco JL, Alcamí J, et al. Documento de consenso de GESIDA sobre la utilización de los estudios de resistencias en la práctica clínica. *Enferm Infecc Microbiol Clin* 2001; 19:53-60

**Gaynor R**. Cellular transcription factors involved in the regulation of HIV-1 gene expression. *AIDS*. 1992 Apr;6(4):347-63. Review.

**Gao F**, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson G, Sodroski J, Morgado M, Galvao-Castro B, von Briesen H, et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. *J Virol*. 1996 Mar;70(3):1651-67.

**Gazzard B**. The basics of antiretroviral prescribing. *J Infect*. 1998 May;36(3):ii-iv.

**Geels MJ**, Cornelissen M, Schuitemaker H, Anderson K, Kwa D, Maas J, Dekker JT, Baan E, Zorgdrager F, van den Burg R, van Beelen M, Lukashov VV, Fu TM, Paxton WA, van der Hoek L, Dubey SA, Shiver JW, Goudsmit J. Identification of

sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. *J Virol.* 2003 Dec;77(23):12430-40.

**Giorgi JV**, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. *J Acquir Immune Defic Syndr.* 1993 Aug;6(8):904-12.

**Gomez-Cano M**, Rubio A, Puig T, Perez-Olmeda M, Ruiz L, Soriano V, Pineda JA, Zamora L, Xaus N, Clotet B, Leal M. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. *AIDS.* 1998 Jun 18;12(9):1015-20.

**Goodenow M**, Huet T, Saurin W, Kwok S, Sninsky J, Wain-Hobson S. HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. *J Acquir Immune Defic Syndr.* 1989;2(4):344-52.

**Gottlieb MS**, Schroff R, Schrandt HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. *N Engl J Med.* 1981; 305:1425-9.

**Graham N**, Peeters M, Verbiest W, et al. The virtual phenotype is an independent predictor of clinical response. Program and abstracts of the 8<sup>th</sup> Conference on Retroviruses and Opportunistic Infections. Chicago 2001. Abstract 524

**a.Graziosi C**, Pantaleo G, Demarest JF, Cohen OJ, Vaccarezza M, Butini L, Montroni M, Fauci AS. HIV-1 infection in the lymphoid organs. *AIDS.* 1993 Nov;7 Suppl 2:S53-8.

**b.Graziosi C**, Pantaleo G, Butini L, Demarest JF, Saag MS, Shaw GM, Fauci AS. Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. *Proc Natl Acad Sci U S A.* 1993 Jul 15;90(14):6405-9.

**Green WC**. The molecular biology of human immunodeficiency virus type 1 infection. *N Engl J Med.* 1991; 324:08-17.

**Groenink M**, Andeweg AC, Fouchier RA, Broersen S, van der Jagt RC, Schuitemaker H, de Goede RE, Bosch ML, Huisman HG, Tersmette M. Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. *J Virol.* 1992 Oct;66(10):6175-80.

**Gulick R**, Mellors J, Havlir D et al. Potent and sustained antiretroviral activity of indinavir, zidovudine and lamivudine. XI International Conference on AIDS. Vancouver (Canada) 1996

**Gunthard H**, Wong J, Ignacio C, et al. HIV replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. *J Virol* 1998; 72:2422-2428

**Gupta P**, Kingsley L, Armstrong J, Ding M, Cottrill M, Rinaldo C. Enhanced expression of human immunodeficiency virus type 1 correlates with development of AIDS. *Virology*. 1993 Oct;196(2):586-95.

**Haase AT**, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, Cavert W, Gebhard K, Staskus K, Zhang ZQ, Dailey PJ, Balfour HH Jr, Erice A, Perelson AS. Quantitative image analysis of HIV-1 infection in lymphoid tissue. *Science*. 1996 Nov 8;274(5289):985-9.

**Haase AT**. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. *Annu Rev Immunol*. 1999;17:625-56.

**Haase AT**. Transmission and propagation of SIV and HIV infection in vivo. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, USA. February 2002 [abstract L9].

**Hammer SM**, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. *AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med*. 1996 Oct 10;335(15):1081-90.

**Hammer S**, Peeters M, Harrigan R, et al. Virtual phenotype is predictive of treatment failure in treatment experienced patients. Program and abstracts of the 5<sup>th</sup> International Workshop on HIV Drug Resistance and Treatment Strategies. Arizona 2001. Abstract 142

**Hanh BH**, Shaw GM, Arya SK, Popovic M, Gallo RC, Wong-Stall F. Molecular cloning and characterization of the HTLV-III virus associated with AIDS. *Nature*. 1984. 312, 166-169.

**Hanh BH**, Gonda MA, Shaw GM, Popovic M, Hoxie JA, Gallo RC, Wong-Stall F. Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: Different virus exhibit greatest divergence in their envelope. *Proceedings of the National Academy of Science of EEUU* 1985.82, 4813-4817.

**Hanh BH**, Shaw GM, Taylor ME, Redfiel RR, Markham PD, Salahuddin SZ, Wong-Stall F, Gallo RC, Parks ES, Parks WP. Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. *Science* 1986. 232, 1548-1553.

**Hanna GJ**, D'Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.



Clin Infect Dis. 2001 Mar 1;32(5):774-82. Epub 2001 Feb 28.

**Harrigan PR**, Whaley M, Montaner JS.  
Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy.  
AIDS. 1999 May 28;13(8):F59-62.

**Harris M**, Rachlis A, Shillington A et al. Long term supression of HIV in plasma with a combination of two nucleosides and nevirapine. Abstract I86. 37<sup>th</sup> ICAAC, Toronto, Ontario, Canada. 1997

**Harrowe G**, Cheng-Mayer C.  
Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1. Virology. 1995 Jul 10;210(2):490-4.

**Haseltine WA**, Wong-Staal F. The molecular biology of the AIDS virus. Scientific American 1988; 259:34-32

**Haslett PA**, Nixon DF, Shen Z, Larsson M, Cox WI, Manandhar R, Donahoe SM, Kaplan G.  
Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy.  
J Infect Dis. 2000 Apr;181(4):1264-72. Epub 2000 Apr 05.

**Haubrich RH**, Currier JS, Forthal DN, Beall G, Kemper CA, Johnson D, Dube MP, Hwang J, Leedom JM, Tilles J, McCutchan JA; California Collaborative Treatment Group.  
A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy.  
Clin Infect Dis. 2001 Oct 1;33(7):1060-8. Epub 2001 Sep 05.

**Havlir DV**, Lange JM.  
New antiretrovirals and new combinations.  
AIDS. 1998;12 Suppl A:S165-74.

**Havlir DV**, Hellmann NS, Petroulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000; 283:229-234

**Hecht FM**, Gran RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple RT and protease inhibitors. N Engl J Med 1998; 339:307-331

**Hellerstein M**, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E, Schmidt D, Hoh R, Neese R, Macallan D, Deeks S, McCune JM.  
Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med. 1999 Jan;5(1):83-9.

**Hertogs K**, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B, Pauwels R.

A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. *Antimicrob Agents Chemother.* 1998 Feb;42(2):269-76.

**Hirsch MS**, Richman DD.  
The role of genotypic resistance testing in selecting therapy for HIV  
*JAMA.* 2000 Oct 4;284(13):1649-50.

**Ho DD**, Moudgil T, Robin HS, Alam M, Wallace BJ, Mizrahi Y.  
Human immunodeficiency virus type 1 in a seronegative patient with visceral Kaposi's sarcoma and hypogammaglobulinemia.  
*Am J Med.* 1989 Mar;86(3):349-51.

**Ho DD.**  
HIV-1 dynamics in vivo.  
*J Biol Regul Homeost Agents.* 1995 Jul-Sep;9(3):76-7.

**Ho DD**, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M.  
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. *Nature.* 1995 Jan 12;373(6510):123-6.

**Ho DD.**  
Therapy of HIV infections: problems and prospects.  
*Bull N Y Acad Med.* 1996 Summer;73(1):37-45.

**Hockett RD**, Kilby JM, Derdeyn CA, Saag MS, Sillers M, Squires K, Chiz S, Nowak MA, Shaw GM, Bucy RP.  
Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA.  
*J Exp Med.* 1999 May 17;189(10):1545-54.

**Hoffman NG**, Seillier-Moisewitsch F, Ahn J, Walker JM, Swanstrom R.  
Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop.  
*J Virol.* 2002 Apr;76(8):3852-64.

**Hoffman TL**, Doms RW.  
Chemokines and coreceptors in HIV/SIV-host interactions.  
*AIDS.* 1998;12 Suppl A:S17-26.

**Imamichi H**, Crandall KA, Natarajan V, Jiang MK, Dewar RL, Berg S, Gaddam A, Bosche M, Metcalf JA, Davey RT Jr, Lane HC.  
Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy.  
*J Infect Dis.* 2001 Jan 1;183(1):36-50. Epub 2000 Dec 08.

**Imrie A**, Beveridge A, Genn W, et al. Transmission of HIV-1 resistant to nevirapine and zidovudine: Sydney primary HIV infection Study Group. *J Infect Dis* 1997; 175:1502-1506

**Iribarren JA**, Ramos JT, Guerra L, Coll O, de Jose MI, Domingo P, Fortuny C, Miralles P, Parras F, Pena JM, Rodrigo C, Vidal R. Prevention of vertical transmission and treatment of infection caused by the human immunodeficiency virus in the pregnant woman. Recommendations of the Study Group for AIDS, Infectious Diseases, and Clinical Microbiology, the Spanish Pediatric Association, the National AIDS Plan and the Spanish Gynecology and Obstetrics Society. *Enferm Infecc Microbiol Clin*. 2001 Aug-Sep;19(7):314-35.

**Jansson M**, Popovic M, Karlsson A, Cocchi F, Rossi P, Albert J, Wigzell H. Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. *Proc Natl Acad Sci U S A* 1996 Dec 24;93(26):15382-7

**Japour AJ**, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, Kuritzkes DR. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. *J Infect Dis*. 1995 May;171(5):1172-9.

**Jurriaans S**, Dekker JT, de Ronde A. HIV-1 viral DNA load in peripheral blood mononuclear cells from seroconverters and long-term infected individuals. *AIDS*. 1992 Jul;6(7):635-41.

**Jurriaans S**, Van Gemen B, Weverling GJ, Van Strijp D, Nara P, Coutinho R, Koot M, Schuitemaker H, Goudsmit J. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? *Virology*. 1994 Oct;204(1):223-33.

**Kalams SA**, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, Walker BD. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. *J Virol*. 1999 Aug;73(8):6721-8.

**Kampinga GA**, Simonon A, Van de Perre P, Karita E, Msellati P, Goudsmit J. Primary infections with HIV-1 of women and their offspring in Rwanda: findings of heterogeneity at seroconversion, coinfection, and recombinants of HIV-1 subtypes A and C. *Virology*. 1997 Jan 6;227(1):63-76.

**Kaplan JE**, Masur H, Jaffe HW, Holmes KK. Reducing the impact of opportunistic infections in patients with HIV infection. New guidelines. *JAMA*. 1995 Jul 26;274(4):347-8.

**Katlama C**. Consequences for the management of cytomegalovirus. *AIDS*. 1996 Nov;10 Suppl 1:S43-6.

- Katzenstein DA**, Holodniy M, Israelski DM, Sengupta S, Mole LA, Bubp JL, Merigan TC.  
Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment.  
*J Acquir Immune Defic Syndr.* 1992;5(2):107-12.
- Katzenstein TL**, Pedersen C, Nielsen C, Lundgren JD, Jakobsen PH, Gerstoft J.  
Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome.  
*AIDS.* 1996 Feb;10(2):167-73.
- Keet IP**, Tang J, Klein MR, LeBlanc S, Enger C, Rivers C, Apple RJ, Mann D, Goedert JJ, Miedema F, Kaslow RA. Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men. *J Infect Dis.* 1999 Aug;180(2):299-309.
- Kellam P**, Larder BA. Recombinant virus assay: a rapid phenotypic assay for assesment of drug susceptibility of HIV-1 isolates. *Antimicrob Agents Chemother* 1994; 38:23-30
- Kellam P**, Larder BA. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. *J Virol.* 1995
- Kempf DJ**, Rode RA, Xu Y, et al. The duration of viral supression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. *AIDS* 1998; 12:F9-F14
- Kilby JM**, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS.  
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. *Nat Med.* 1998 Nov;4(11):1302-7.
- Kim R**, Fromm F, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. *J Clin Invest* 1998; 101:289-294.
- Kinter AL**, Umscheid CA, Arthos J, Cicala C, Lin Y, Jackson R, Donoghue E, Ehler L, Adelsberger J, Rabin RL, Fauci AS. HIV envelope induces virus expression from resting CD4+ T cells isolated from HIV-infected individuals in the absence of markers of cellular activation or apoptosis. *J Immunol.* 2003 Mar 1;170(5):2449-55.
- Khoo SH**, Gibbons SE, Back DJ. Therapeutic drug monitoring as a tool in treating HIV infection. *AIDS.* 2001;15 Suppl 5:S171-81.
- Knobel H**, Carmona A, Grau S, Pedro-Botet J, Diez A.  
Adherence and effectiveness of highly active antiretroviral therapy.  
*Arch Intern Med.* 1998 Sep 28;158(17):1953.
- Koot M**, Vos AH, Keet RP, de Goede RE, Dercksen MW, Terpstra FG, Coutinho RA, Miedema F, Tersmette M.

- HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. *AIDS*. 1992 Jan;6(1):49-54.
- Korber BT**, MacInnes K, Smith RF, Myers G. Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. *J Virol*. 1994 Oct;68(10):6730-44.
- Koup RA**. Virus escape from CTL recognition. *J Exp Med*. 1994 Sep 1;180(3):779-82.
- Kowalski M**, Potz J, Basiripour L, Dorfman T, Goh WC, Terwilliger E, Dayton A, Rosen C, Haseltine W, Sodroski J. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. *Science*. 1987 Sep 11;237(4820):1351-5.
- Koyanagi Y**, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen IS. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. *Science*. 1987 May 15;236(4803):819-22.
- Kozak SL**, Platt EJ, Madani N, Ferro FE Jr, Peden K, Kabat D. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. *J Virol*. 1997 Feb;71(2):873-82.
- Kozal MJ**, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. *Ann Intern Med*. 1994 Aug 15;121(4):263-8.
- Kramer A**, Wiktor SZ, Fuchs D, Milstien S, Gail MH, Yellin FJ, Biggar RJ, Wachter H, Kaufman S, Blattner WA, et al. Neopterin: a predictive marker of acquired immune deficiency syndrome in human immunodeficiency virus infection. *J Acquir Immune Defic Syndr*. 1989;2(3):291-6.
- Kure K**, Llana JF, Lyman WD, Soeiro R, Weidenheim KM, Hirano A, Dickson DW. Human immunodeficiency virus-1 infection of the nervous system: an autopsy study of 268 adult, pediatric, and fetal brains. *Hum Pathol*. 1991 Jul;22(7):700-10.
- Kuritzkes DR**, Bell S, Bakhtiari M. Rapid CD4+ cell decline after sexual transmission of a zidovudine-resistant syncytium-inducing isolate of HIV-1. *AIDS*. 1994 Jul;8(7):1017-9.
- Lanier ER**, Hellmann, Scott J et al. Determination of clinically relevant phenotypic resistance "cutoff" for abacavir using the PhenoSense assay. Program and abstracts of the 8<sup>th</sup> Conference on Retroviruses and Opportunistic Infections. Chicago 2001. Abstract 254

- Lange JM**, de Wolf F, Krone WJ, Danner SA, Coutinho RA, Goudsmit J. Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline. *AIDS*. 1987 Sep;1(3):155-9.
- Larder B**, De Vroey V, Dehertogh P, et al. Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database. Abstract 59. *Antiviral Therapy* 1999; 4 (suppl 1):41
- Larder BA**, Hertogs K, Bloor S, van den Eynde CH, DeCian W, Wang Y, Freimuth WW, Tarpley G. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. *AIDS*. 2000 Sep 8;14(13):1943-8.
- b.Larder** i col., *Antiviral Therapy* 2000; 5 Suppl. 3: 49 Abs 63
- Lasky LA**, Nakamura G, Smith DH, Fennie C, Shimasaki C, Patzer E, Berman P, Gregory T, Capon DJ. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. *Cell*. 1987 Sep 11;50(6):975-85.
- Ledergerber B**, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. *Swiss HIV Cohort Study. Lancet* 1999; 353:863-8
- Lee CG**, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. *Biochemistry* 1998; 37:3594-3601
- Levacher M**, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, Bach BA. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. *Clin Exp Immunol*. 1992 Dec;90(3):376-82.
- Levy JA**, Hoffman AD, Framer SM, et al. Isolation of lymphocytophatic retroviruses from San Francisco patients with AIDS. *Science* 1984; 225:840-2.
- Levy JA**. Pathogenesis of human immunodeficiency virus infection. *Microbiol Rev* 1993 Mar;57(1):183-289.
- Levy JA**, Hsueh F, Blackbourn DJ, Wara D, Weinrub PS. CD8 cell noncytotoxic antiviral activity in human immunodeficiency virus-infected and -uninfected children. *J Infect Dis*. 1998 Feb;177(2):470-2.
- Lew J**, Reichelderfer P, Fowler M, Bremer J, Carrol R, Cassol S, Chernoff D, Coombs R, Cronin M, Dickover R, Fiscus S, Herman S, Jackson B, Kornegay J, Kovacs A, McIntosh K, Meyer W, Michael N, Mofenson L, Moye J, Quinn T, Robb M, Vahey M, Weiser B, Yeghiazarian T. Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop

Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics.

J Clin Microbiol. 1998 Jun;36(6):1471-9.

**Lewin SR**, Vesanen M, Kostrikis L, Hurley A, Duran M, Zhang L, Ho DD, Markowitz M.

Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy.

J Virol. 1999 Jul;73(7):6099-103.

**Li TS**, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet. 1998 Jun 6;351(9117):1682-6.

**Lifson AR**, Buchbinder SP, Sheppard HW, Mawle AC, Wilber JC, Stanley M, Hart CE, Hessel NA, Holmberg SD.

Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: immunologic and virologic characteristics.

J Infect Dis. 1991 May;163(5):959-65.

**Lifson AR**, Hessel NA, Buchbinder SP, O'Malley PM, Barnhart L, Segal M, Katz MH, Holmberg SD.

Serum beta 2-microglobulin and prediction of progression to AIDS in HIV infection.

Lancet. 1992 Jun 13;339(8807):1436-40.

**Liszewicz J**, Jessen H, Finzi D, Siliciano RF, Lori F.

HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor.

Lancet. 1998 Jul 18;352(9123):199-200.

**Liszewicz J**, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, Walker B, Lori F.

Control of HIV despite the discontinuation of antiretroviral therapy.

N Engl J Med. 1999 May 27;340(21):1683-4.

**Little SJ**, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV-1 infection. J Am Med Association 1999; 282:1142-1149

**Lopez Bernaldo de Quiros JC**, Miro JM, Pena JM, Podzamczar D, Alberdi JC, Martinez E, Cosin J, Claramonte X, Gonzalez J, Domingo P, Casado JL, Ribera E; Grupo de Estudio del SIDA 04/98. A randomized trial of the discontinuation of primary and secondary prophylaxis against *Pneumocystis carinii* pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med. 2001 Jan 18;344(3):159-67.

**Lori F**, Malykh A, Cara A, Sun D, Weinstein JN, Liszewicz J, Gallo RC.

Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication.

Science. 1994 Nov 4;266(5186):801-5.

- Lori F**, Jessen H, Lieberman J, Finzi D, Rosenberg E, Tinelli C, Walker B, Siliciano RF, Lisziewicz J.  
Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir.  
*J Infect Dis.* 1999 Dec;180(6):1827-32.
- Lori F**, Lewis MG, Xu J, Varga G, Zinn DE Jr, Crabbs C, Wagner W, Greenhouse J, Silvera P, Yalley-Ogunro J, Tinelli C, Lisziewicz J.  
Control of SIV rebound through structured treatment interruptions during early infection.  
*Science.* 2000 Nov 24;290(5496):1591-3.
- Lucas GM**, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. *Ann Intern Med.* 1999 Jul 20;131(2):81-7.
- Lukashov VV**, Kuiken CL, Goudsmit J.  
Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. *J Virol.* 1995 Nov;69(11):6911-6.
- Lukashov VV**, Goudsmit J.  
HIV heterogeneity and disease progression in AIDS: a model of continuous virus adaptation. *AIDS.* 1998;12 Suppl A:S43-52.
- Maddon PJ**, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. *Cell.* 1986 Nov 7;47(3):333-48.
- Mansky LM**, Temin HM.  
Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.  
*Virol.* 1995 Aug;69(8):5087-94.
- Margolis D**, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield R.  
Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity.  
*J Acquir Immune Defic Syndr.* 1999 Aug 15;21(5):362-70.
- Margolis DM**, Kewn S, Coull JJ, Ylisastigui L, Turner D, Wise H, Hossain MM, Lanier ER, Shaw LM, Back D.  
The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. *J Acquir Immune Defic Syndr.* 2002 Sep 1;31(1):45-9.
- Martinez E**, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A, Gatell JM.  
Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. *Lancet.* 2001 Feb 24;357(9256):592-8.



- a. Martínez-Picado J**, Morales-Lopetegi K, Wrin T, Prado JG, Frost SD, Petropoulos CJ, Clotet B, Ruiz L.  
Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. *AIDS*. 2002 Apr 12;16(6):895-9.
- b Martínez-Picado J**, Frost SD, Izquierdo N, Morales-Lopetegi K, Marfil S, Puig T, Cabrera C, Clotet B, Ruiz L.  
Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals. *J Virol*. 2002 Dec;76(23):12344-8.
- Masur H**, Ognibene FP, Yarchoan R, Shelhamer JH, Baird BF, Travis W, Suffredini AF, Deyton L, Kovacs JA, Falloon J, et al.  
CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. *Ann Intern Med*. 1989 Aug 1;111(3):223-31
- Maurer B**, Flugel RM.  
Genomic organization of the human spumaretrovirus and its relatedness to AIDS and other retroviruses. *AIDS Res Hum Retroviruses*. 1988 Dec;4(6):467-73.
- Michael NL**, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, Sheppard HW.  
The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. *Nat Med*. 1997 Mar;3(3):338-40.
- McMichael AJ**, Rowland-Jones SL.  
Cellular immune responses to HIV.  
*Nature*. 2001 Apr 19;410(6831):980-7.
- Mellors JW**, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP, Gupta P.  
Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. *Ann Intern Med*. 1995 Apr 15;122(8):573-9.
- Mellors JW**, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA.  
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. *Science*. 1996 May 24;272(5265):1167-70.
- Mellors JW**, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR Jr.  
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med*. 1997 Jun 15;126(12):946-54.
- Melnick D**, Rosenthal J, Cameron M, et al. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy (ART) in heavily experienced patients. Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, California. Abstract 786.
- Menendez-Arias L**, Mas A, Domingo E.  
Cytotoxic T-lymphocyte responses to HIV-1 reverse transcriptase (review)  
*Viral Immunol*. 1998;11(4):167-81.
- a. Meynard L**, Miedema F.  
Programmed death of T cells in the course of HIV infection.

Adv Exp Med Biol. 1995;374:115-20.

**b. Meyaard L**, Miedema F.

Programmed death of T cells in HIV infection: result of immune activation?  
Curr Top Microbiol Immunol. 1995;200:213-21.

**Meynard JL**, Vray M, Morand-Joubert L, et al. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: a randomized trial (NARVAL, ANRS 088). *Antivir Ther.* 2000;5(suppl 3):67.

**Miedema F**, Meyaard L, Koot M, Klein MR, Roos MT, Groenink M, Fouchier RA, Van't Wout AB, Tersmette M, Schellekens PT, et al.  
Changing virus-host interactions in the course of HIV-1 infection.  
*Immunol Rev.* 1994 Aug;140:35-72.

**Miró JM**, Pumarola T, García F, Arnedo M, Vidal C, Lozano L. i col. Prevalence of transmission of HIV-1 drug resistance mutations in patients with primary HIV-1 infection in Barcelona (Spain). XIII International AIDS Conference. Durban (South Africa), 2000. Resumen TuPeB3270;

**Mofenson LM**, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J, Moyer J Jr, Reichelderfer P, Harris DR, Fowler MG, Mathieson BJ, Nemo GJ.  
Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. *N Engl J Med.* 1999 Aug 5;341(6):385-93.

**Mohri H**, Shingh MK, Ching GTW et al. Quantitation of zidovudine-resistant HIV-1 in the blood of treated and untreated patients. *Proc Natl Acad Sci USA* 1995; 373:123-126.

**Molla A**, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. *Nature Medicine* 1996; 2:760-766

**Montaner JS**, DeMasi R, Hill AM.

The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.  
*AIDS.* 1998 Mar 26;12(5):F23-8.

**Montefiori DC**, Safrit JT, Lydy SL, Barry AP, Biliska M, Vo HT, Klein M, Tartaglia J, Robinson HL, Rovinski B.

Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. *J Virol.* 2001 Jul;75(13):5879-90.

**Moore CB**, John M, James IR, Christiansen FT, Witt CS, Mallal SA.

Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level.  
*Science.* 2002 May 24;296(5572):1439-43.

**Moriuchi H**, Moriuchi M, Mizell SB, Ehler LA, Fauci AS. In vitro reactivation of human immunodeficiency virus 1 from latently infected, resting CD4+ T cells after bacterial stimulation. *J Infect Dis.* 2000 Jun;181(6):2041-4. Epub 2000 May 25.

- Murphy PM.** The molecular biology of leukocyte chemoattractant receptors. *Annu Rev Immunol.* 1994 ; 12 :593-633.
- Nájera I,** Richman DD, Olivares I et al. Natural Occurrence of drug resistance mutations in the reverse transcriptase of HIV-1 isolates. *AIDS Res Hum Retrov* 1994; 10:1475-1484
- Najera I,** Holguin A, Quinones-Mateu ME, Munoz-Fernandez MA, Najera R, Lopez-Galindez C, Domingo E.  
Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. *J Virol.* 1995 Jan;69(1):23-31.
- Neumann AU,** Tubiana R, Calvez V, Robert C, Li TS, Agut H, Autran B, Katlama C. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. *AIDS.* 1999 Apr 16;13(6):677-83.
- Nijhuis M,** Boucher CA, Schipper P, Leitner T, Schuurman R, Albert J.  
Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. *Proc Natl Acad Sci U S A.* 1998 Nov 24;95(24):14441-6.
- Nowak MA,** Bangham CR.  
Population dynamics of immune responses to persistent viruses. *Science.* 1996 Apr 5;272(5258):74-9.
- Oberlin E,** Amara A, Bachelier F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. *Nature.* 1996 Aug 29;382(6594):833-5.
- Ogg GS,** Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF, McMichael AJ.  
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. *Science.* 1998 Mar 27;279(5359):2103-6.
- Orenstein JM,** Fox C, Tenner-Racz K, Racz P.  
Is HIV found in the cytoplasm of dendritic cells? *Am J Pathol.* 1997 Oct;151(4):1173-6.
- Ortiz GM,** Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, Kuebler PJ, Donahoe SM, Demoitie MA, Kakimoto WM, Ketas T, Clas B, Heymann JJ, Zhang L, Cao Y, Hurley A, Moore JP, Ho DD, Markowitz M.  
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. *J Clin Invest.* 1999 Sep;104(6):R13-8.
- Ortiz GM,** Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF.  
Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13288-93. Epub 2001 Oct 30.

**Ostrowski MA**, Krakauer DC, Li Y, Justement SJ, Learn G, Ehler LA, Stanley SK, Nowak M, Fauci AS. Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. *J Virol*. 1998 Oct;72(10):7772-84.

**Overbaugh J**, Anderson RJ, Ndinya-Achola JO, Kreiss JK. Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood. *AIDS Res Hum Retroviruses*. 1996 Jan 20;12(2):107-15.

**Oxenius A**, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, Sontag G, Sewell AK, Phillips RE. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. *Proc Natl Acad Sci U S A*. 2000 Mar 28;97(7):3382-7.

**Pakker NG**, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, Leonard JM, Danner SA, Miedema F, Schellekens PT. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. *Nat Med*. 1998 Feb;4(2):208-14.

**Palella FJ Jr**, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med*. 1998 Mar 26;338(13):853-60.

**Pantaleo G**, Graziosi C, Butini L, Pizzo PA, Schnittman SM, Kotler DP, Fauci AS. Lymphoid organs function as major reservoirs for human immunodeficiency virus. *Proc Natl Acad Sci U S A*. 1991 Nov 1;88(21):9838-42.

**Pantaleo G**, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. *Nature*. 1993 Mar 25;362(6418):355-8.

**Pantaleo G**, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, Montefiori D, Orenstein JM, Fox C, Schragger LK, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. *N Engl J Med*. 1995 Jan 26;332(4):209-16.

**Papasavvas E**, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. *J Infect Dis*. 2000 Sep;182(3):766-75. Epub 2000 Aug 17.

**Papasavvas E**, Grant RM, Sun J, Mackiewicz A, Pistilli M, Gallo C, Kostman JR, Mounzer K, Shull J, Montaner LJ. Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients. *AIDS*. 2003 Nov 7;17(16):2337-43.

**Parkin NT**, Chappey C, Maroldo L, et al. Incidence and nature of phenotype-genotype discordance: Maximizing the utility of resistance testing. Program and abstracts of the 9<sup>th</sup> Conference on Retroviruses and Opportunistic Infections. Seattle 2002. Abstract 580

**Patterson BK**, Till M, Otto P, Goolsby C, Furtado MR, McBride LJ, Wolinsky SM. Detection of HIV-1 DNA and messenger RNA in individual cells by PCR-driven in situ hybridization and flow cytometry. *Science*. 1993 May 14;260(5110):976-9.

**Peliska JA**, Benkovic SJ. Mechanism of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase. *Science*. 1992 Nov 13;258(5085):1112-8.

**Perelson AS**, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. *Science*. 1996 Mar 15;271(5255):1582-6

**Perelson AS**, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. Decay characteristics of HIV-1-infected compartments during combination therapy. *Nature*. 1997 May 8;387(6629):188-91.

**b Perelson AS**, Essunger P, Ho DD. Dynamics of HIV-1 and CD4+ lymphocytes in vivo. *AIDS*. 1997;11 Suppl A:S17-24.

**Persaud D**, Pierson T, Ruff C, Finzi D, Chadwick KR, Margolick JB, Ruff A, Hutton N, Ray S, Siliciano RF. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. *J Clin Invest*. 2000 Apr;105(7):995-1003.

**Persaud D**, Zhou Y, Siliciano JM, Siliciano RF. Latency in human immunodeficiency virus type 1 infection: no easy answers. *J Virol*. 2003 Feb;77(3):1659-65.

**Peterson A**, Seed B. Genetic analysis of monoclonal antibody and HIV binding sites on the human lymphocyte antigen CD4. *Cell*. 1988 Jul 1;54(1):65-72.

**Petrella M**, Wainberg MA. Might the M184V substitution in HIV-1 RT confer clinical benefit? *AIDS Rev*. 2002 Oct-Dec;4(4):224-32.

**Piatak M Jr**, Yang LC, Luk KC, Lifson JD, Saag MS, Clark SJ, Kappes JC, Hahn BH, Shaw GM. Viral dynamics in primary HIV-1 infection. *Lancet*. 1993 Apr 24;341(8852):1099.

**Piccini G**, Foli A, Comolli G, Lisziewicz J, Lori F.

Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes. *J Virol.* 2002 Mar;76(5):2274-8.

**Pitcher CJ**, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, Picker LJ.  
HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. *Nat Med.* 1999 May;5(5):518-25.

**Picker LJ.**  
Regulation of tissue-selective T-lymphocyte homing receptors during the virgin to memory/effector cell transition in human secondary lymphoid tissues. *Am Rev Respir Dis.* 1993 Dec;148(6 Pt 2):S47-54.

**Pierson T**, McArthur J, Siliciano RF.  
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. *Annu Rev Immunol.* 2000;18:665-708.

**Pierson TC**, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF.  
Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. *J Virol.* 2002 Apr;76(8):4138-44.

**Piscitelli SC**, Wells MJ, Metcalf JA, Baseler M, Stevens R, Davey RT Jr.  
Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients. *Pharmacotherapy.* 1996 Sep-Oct;16(5):754-9.

**Plana M**, Garcia F, Gallart T, Miro JM, Gatell JM.  
Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study. *Lancet.* 1998 Oct 10;352(9135):1194-5.

**Plana M**, Garcia F, Gallart T, Tortajada C, Soriano A, Palou E, Maleno MJ, Barcelo JJ, Vidal C, Cruceta A, Miro JM, Gatell JM.  
Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. *AIDS.* 2000 Sep 8;14(13):1921-33.

**Pomerantz RJ**, Trono D, Feinberg MB, Baltimore D. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. *Cell.* 1990 Jun 29;61(7):1271-6.

**Polis MA**, Masur H.  
Predicting the progression to AIDS. *Am J Med.* 1990 Dec;89(6):701-5.

**Pollakis G**, Kang S, Kliphuis A, Chalaby MI, Goudsmit J, Paxton WA.  
N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. *J Biol Chem.* 2001 Apr 20;276(16):13433-41.

- Pozni A**, Gazzard D, Churchill D, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. London 2000; <http://www.aidsmap.com>
- Popovic M**, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. *Science*. 1984; 224: 497-500.
- Powderly WG**, Sesion M, Conant M et al. The efficacy of viracept in pivotal phase I/II double-blind randomized controlled trials as monotherapy and in combination with D4T or AZT/3TC. 4th Conference on Retroviruses and Opportunistic Infections. Washington DC (USA) 1997
- Preston BD**, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. *Science* 1988; 242:1168-71
- Price DA**, O'callaghan CA, Whelan JA, Easterbrook PJ, Phillips RE. Cytotoxic T lymphocytes and viral evolution in primary HIV-1 infection. *Clin Sci (Lond)* 1999, 97(6): 707-18.
- Psallidopoulos MC**, Schnittman SM, Thompson LM 3rd, Baseler M, Fauci AS, Lane HC, Salzman NP. Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals. *J Virol*. 1989 Nov;63(11):4626-31.
- Puig T**, Perez-Olmeda M, Rubio A, Ruiz L, Briones C, Franco JM, Gomez-Cano M, Stuyver L, Zamora L, Alvarez C, Leal M, Clotet B, Soriano V. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group. *AIDS*. 2000 Apr 14;14(6):727-32.
- Quinn TC**, Kline RL, Halsey N, Hutton N, Ruff A, Butz A, Boulos R, Modlin JF. Early diagnosis of perinatal HIV infection by detection of viral-specific IgA antibodies. *JAMA*. 1991 Dec 25;266(24):3439-42.
- Quinn TC**, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. *N Engl J Med*. 2000 Mar 30;342(13):921-9.
- Ramratnam B**, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken CA, Perelson AS, Markowitz M, Ho DD. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. *Nat Med*. 2000 Jan;6(1):82-5.
- Ravot E**, Tambussi G, Jessen H, Tinelli C, Lazzarin A, Lisziewicz J, Lori F. Effects of hydroxyurea on T cell count changes during primary HIV infection. *AIDS*. 2000 Mar 31;14(5):619-22.

**Reijers MH**, Weverling GJ, Jurriaans S, Wit FW, Weigel HM, Ten Kate RW, Mulder JW, Frissen PH, van Leeuwen R, Reiss P, Schuitemaker H, de Wolf F, Lange JM.

Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. *Lancet*. 1998 Jul 18;352(9123):185-90.

**Reinhart TA**, Rogan MJ, Viglianti GA, Rausch DM, Eiden LE, Haase AT.

A new approach to investigating the relationship between productive infection and cytopathicity in vivo.

*Nat Med*. 1997 Feb;3(2):218-21.

**Rezza G**, Lazzarin A, Angarano G, Sinicco A, Pristera R, Ortona L, Barbanera M, Gafa S, Tirelli U, Salassa B, et al.

The natural history of HIV infection in intravenous drug users: risk of disease progression in a cohort of seroconverters.

*AIDS*. 1989 Feb;3(2):87-90.

**Richman DD**.

Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus.

*Am J Med*. 1990 May 21;88(5B):8S-10S.

**Richman DD**, Havlir D, Corbeil J et al. Nevirapine resistance mutations of HIV-1 selected during therapy. *J Virol* 1994; 68:1660-1666

**Richman DD**.

How drug resistance arises.

*Sci Am*. 1998 Jul;279(1):88.

**Rizzardi GP**, Vaccarezza M, Capiluppi B, Tambussi G, Lazzarin A, Pantaleo G.

Cyclosporin A in combination with HAART in primary HIV-1 infection.

*J Biol Regul Homeost Agents*. 2000 Jan-Mar;14(1):79-81.

**Rodriguez-Rosado R**, Briones C, Soriano V.

Introduction of HIV drug-resistance testing in clinical practice.

*AIDS*. 1999 Jun 18;13(9):1007-14.

**Rosenberg ES**, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD.

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

*Science*. 1997 Nov 21;278(5342):1447-50.

**Rosenberg ES**, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, Robbins GK, D'Aquila RT, Goulder PJ, Walker BD.

Immune control of HIV-1 after early treatment of acute infection.

*Nature*. 2000 Sep 28;407(6803):523-6.

**Rubio R**, Berenguer J, Miro JM, Antela A, Iribarren JA, Gonzalez J, Guerra L, Moreno S, Arrizabalaga J, Clotet B, Gatell JM, Laguna F, Martinez E, Parras F, Santamaria JM, Tuset M, Viciano P. Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral



REFERÈNCIES

**Adams B**, Holte S, Randolph T, Banks HT. STI control of HIV infection. 1<sup>st</sup> SIAM Conference on the Life Sciences. Boston, USA. March 2002.

**Alcami J**, Lain de Lera T, Folgueira L, Pedraza MA, Jacque JM, Bachelerie F, Noriega AR, Hay RT, Harrich D, Gaynor RB, et al. Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. *EMBO J*. 1995 Apr 3;14(7):1552-60.

**Altfield M**, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, and al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. *J Exp Med* 2001, 15; 193(2): 169-80.

**Allain JP**, Laurian Y, Paul DA, Senn D. Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs. *Lancet*. 1986 Nov 29;2(8518):1233-6.

**Allain JP**, Frommel D, Bosser C, Gazengel C, Larrieu MJ, Sultan Y. The role of HIV infectivity and composition of factor VIII concentrates on the immunity of haemophiliacs positive for HIV antibodies. *Vox Sang*. 1987;53(1):37-43.

**Asjo B**, Morfeldt-Manson L, Albert J, Biberfeld G, Karlsson A, Lidman K, Fenyo EM. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. *Lancet*. 1986 Sep 20;2(8508):660-2.

**Autran B**, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. *Science*. 1997 Jul 4;277(5322):112-6.

**Autran B**, Carcelain G. AIDS. Boosting immunity to HIV--can the virus help? *Science*. 2000 Nov 3;290(5493):946-9.

**Baxter JD**, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Bein Community Programs for Clinical Research on AIDS. *AIDS*. 2000;14:F83-F93.

**Baggioni M**, Dewald B, Moser B. Interleukin 8 and related chemotactic cytokines CXC and CC chemokines. *Adv Immunol* 1994; 55:97-179.

**Barre-Sinoussi F**, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for

treatment in adult patients with human immunodeficiency virus infection in 2002. *Enferm Infecc Microbiol Clin*. 2002 Jun-Jul;20(6):244-303.

**Ruiz L**, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, Negro E, Sirera G, Tural C, Clotet B.  
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.  
*AIDS*. 2000 Mar 10;14(4):397-403.

**Ruiz L**, Negro E, Domingo P, Paredes R, Francia E, Balague M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J, Clotet B; Spanish Lipodystrophy Group.  
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.  
*J Acquir Immune Defic Syndr*. 2001 Jul 1;27(3):229-36.

**Ruiz L**, Carcelain G, Martinez-Picado J, Frost S, Marfil S, Paredes R, Romeu J, Ferrer E, Morales-Lopetegui K, Autran B, Clotet B.

**Saag MS**, Hahn BH, Gibbons J, et al. Extensive variation of HIV-1 in vivo. *Nature* 1988; 334:440-444

**Saag MS**, Crain MJ, Decker WD, Campbell-Hill S, Robinson S, Brown WE, Leuther M, Whitley RJ, Hahn BH, Shaw GM.  
High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels.  
*J Infect Dis*. 1991 Jul;164(1):72-80.

**Saag MS**.  
Evolving understanding of the immunopathogenesis of HIV.  
*AIDS Res Hum Retroviruses*. 1994 Aug;10(8):887-92.

**Sabino EC**, Delwart E, Lee TH, Mayer A, Mullins JI, Busch MP.  
Identification of low-level contamination of blood as basis for detection of human immunodeficiency virus (HIV) DNA in anti-HIV-negative specimens. *J Acquir Immune Defic Syndr*. 1994 Aug;7(8):853-9.

**Salvatori F**, Masiero S, Giaquinto C, Wade CM, Brown AJ, Chieco-Bianchi L, De Rossi A.  
Evolution of human immunodeficiency virus type 1 in perinatally infected infants with rapid and slow progression to disease.  
*J Virol*. 1997 Jun;71(6):4694-706.

**Saksela K**, Stevens CE, Rubinstein P, Taylor PE, Baltimore D.  
HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. *Ann Intern Med*. 1995 Nov 1;123(9):641-8

**Schacker T**, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. *Ann Intern Med*. 1996 Aug 15;125(4):257-64.

**Shafer RW**, Gonzales MJ, and Brun-Vezinet. Online comparison of HIV-1 drug resistance algorithms identifies rates and causes of discordant interpretation. *Antiviral Ther* 2001; 6(suppl 1):101

**Schellekens PT**, Tersmette M, Roos MT, Keet RP, de Wolf F, Coutinho RA, Miedema F.  
Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype.  
*AIDS*. 1992 Jul;6(7):665-9.

**Schmitz JE**, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA.  
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. *Science*. 1999 Feb 5;283(5403):857-60.

**Schmidt B**, Walter H, Schwingel E, et al. Comparison of different interpretation systems for genotypic HIV-1 drug resistance data. *Antiviral Ther* 2001; 6(suppl 1):101

**Schnittman SM**, Psallidopoulos MC, Lane HC, Thompson L, Baseler M, Massari F, Fox CH, Salzman NP, Fauci AS.  
The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4.  
*Science*. 1989 Jul 21;245(4915):305-8.

**Schnittman SM**, Greenhouse JJ, Psallidopoulos MC, Baseler M, Salzman NP, Fauci AS, Lane HC.  
Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. *Ann Intern Med*. 1990 Sep 15;113(6):438-43.

**Schnittman SM**, Singer KH, Greenhouse JJ, Stanley SK, Whichard LP, Le PT, Haynes BF, Fauci AS.  
Thymic microenvironment induces HIV expression. Physiologic secretion of IL-6 by thymic epithelial cells up-regulates virus expression in chronically infected cells. *J Immunol*. 1991 Oct 15;147(8):2553-8.

**Schockmel GA**, Yerly S, Perrin L.  
Detection of low HIV-1 RNA levels in plasma.  
*J Acquir Immune Defic Syndr Hum Retrovirol*. 1997 Feb 1;14(2):179-83.

**Schuetz JD**, Connelly MC, Sun D, et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiretroviral drugs. *Nat Med* 1999; 5:1048-1051

**Schuurman R**, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, et al.  
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).  
*J Infect Dis*. 1995 Jun;171(6):1411-9.

**Schweighardt B**, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF.

Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. *AIDS*. 2002 Nov 22;16(17):2342-4.

**Sereti I**, Lane HC.

Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies. *Clin Infect Dis*. 2001 Jun 15;32(12):1738-55. Epub 2001 May 16.

**Shi C**, Mellors JW. A recombinant retroviral system for rapid in vivo analysis of HIV-1 susceptibility to reverse transcriptase inhibitors. *Antimicrob Agents Chemother* 1997; 41:2781-2785

Secretaría del Plan Nacional Sobre el SIDA (SPNS). La resistencia a los fármacos antirretrovirales: Utilización de los test en la práctica asistencial. Madrid 2000; <http://www.msc.es/sida/asistencia/resistencias.htm>

**Shafer RW**, Winters MA, Palmer S, Merigan TC.

Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. *Ann Intern Med*. 1998 Jun 1;128(11):906-11.

**Shankarappa R**, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, Huang XL, Mullins JI.

Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. *J Virol*. 1999 Dec;73(12):10489-502.

**Sharkey ME**, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy RP, Kostrikis LG, Haase A, Veryard C, Davaro RE, Cheeseman SH, Daly JS, Bova C, Ellison RT 3rd, Mady B, Lai KK, Moyle G, Nelson M, Gazzard B, Shaunak S, Stevenson M.

Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. *Nat Med*. 2000 Jan;6(1):76-81.

**Sharkey ME**, Stevenson M.

Two long terminal repeat circles and persistent HIV-1 replication. *Curr Opin Infect Dis*. 2001 Feb;14(1):5-11.

**Shioda T**, Oka S, Xin X, Liu H, Harukuni R, Kurotani A, Fukushima M, Hasan MK, Shiino T, Takebe Y, Iwamoto A, Nagai Y.

In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression. *J Virol*. 1997 Jul;71(7):4871-81.

**Shioda T**, Levy JA, Cheng-Mayer C.

Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. *Proc Natl Acad Sci U S A*. 1992 Oct 15;89(20):9434-8.

**Siegal FP**, Lopez C Hammer GS, et al., Severe acquired immunodeficiency syndrome in male homosexuals, manifested by chronic perianal ulcerative Herpes simplex lesions. *N England J Med.* 1981; 305: 1439-43.

**Siliciano JD**, Siliciano RF.  
Latency and viral persistence in HIV-1 infection.  
*J Clin Invest.* 2000 Oct;106(7):823-5.

**Sodroski J**, Rosen C, Wong-Stall F, Salahuddin SZ, et al., Trans-acting transcriptional regulation of human T-cell leukaemia virus type III long terminal repeat. *Science* 1985; 227:171-173.

**Spector SA**, Kennedy C, McCutchan JA, Bozzette SA, Straube RG, Connor JD, Richman DD.  
The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker. *J Infect Dis.* 1989 May;159(5):822-8.

**Spina CA**, Kwoh TJ, Chowes MY, Guatelli JC, Richman DD.  
The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes.  
*J Exp Med.* 1994 Jan 1;179(1):115-23.

**Spina CA**, Guatelli JC, Richman DD. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. *J Virol.* 1995 May;69(5):2977-88.

**Staprans SI**, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM, Feinberg MB.  
Activation of virus replication after vaccination of HIV-1-infected individuals.  
*J Exp Med.* 1995 Dec 1;182(6):1727-37.

**Stein M**, O'Sullivan P, Wachtel T, Fisher A, Mikolich D, Sepe S, Fort G, Carpenter C, Skowron G, Mayer K.  
Causes of death in persons with human immunodeficiency virus infection.  
*Am J Med.* 1992 Oct;93(4):387-90

**Stellbrink HJ**, Zoller B, Fenner T, Lichtenberg G, van Lunzen J, Albrecht H, Thiele HG, Greten H.  
Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment. *AIDS.* 1996 Jul;10(8):849-57.

**Staszewski S**, Miller V, Sabin C, Berger A, Hill AM, Phillips AN.  
Rebound of HIV-1 viral load after suppression to very low levels.  
*AIDS.* 1998 Dec 3;12(17):2360.

**Staszewski S**, Morales J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. *New Engl J Med* 1999; 341:1865-1873

**Takehisa J**, Osei-Kwasi M, Ayisi NK, Hishida O, Miura T, Igarashi T, Brandful J, Ampofo W, Netty VB, Mensah M, Yamashita M, Ido E, Hayami M. Phylogenetic analysis of HIV type 2 in Ghana and intrasubtype recombination in HIV type 2. *AIDS Res Hum Retroviruses*. 1997 May 1;13(7):621-3.

**Takehisa J**, Zekeng L, Ido E, Yamaguchi-Kabata Y, Mboudjeka I, Harada Y, Miura T, Kaptu L, Hayami M. Human immunodeficiency virus type 1 intergroup (M/O) recombination in cameroon. *J Virol*. 1999 Aug;73(8):6810-20.

**Tamalet C**, Lafeuillade A, Tourres C, Yahi N, Vignoli C, De Micco P. Inefficacy of neutralizing antibodies against autologous lymph-node HIV-1 isolates in patients with early-stage HIV infection. *AIDS*. 1994 Mar;8(3):388-9.

**Teeuwssen VJ**, Schalken JJ, van der Groen G, van de Akker R, Goudsmit J, Osterhaus AD. An inhibition enzyme immunoassay using a human monoclonal antibody (K14) reactive with gp41 of HIV-1 for the serology of HIV-1 infections. *AIDS*. 1991 Jul;5(7):893-6

**Tersmette M**, de Goede RE, Al BJ, Winkel IN, Gruters RA, Cuypers HT, Huisman HG, Miedema F. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. *J Virol*. 1988 Jun;62(6):2026-32.

**Tersmette M**, Miedema F. Interactions between HIV and the host immune system in the pathogenesis of AIDS. *AIDS*. 1990;4 Suppl 1:S57-66.

**Tindall B**, Cooper DA. Primary HIV infection: host responses and intervention strategies. *AIDS*. 1991 Jan;5(1):1-14.

**Torre D**, Pugliese A, Orofino G. Effect of highly active antiretroviral therapy on ischemic cardiovascular disease in patients with HIV-1 infection. *Clin Infect Dis*. 2002 Sep 1;35(5):631-2.

**Tortajada C**, Garcia F, Plana M, Gallart T, Maleno MJ, Miro JM, Gatell JM. Comparison of T-cell subsets' reconstitution after 12 months of highly active antiretroviral therapy initiated during early versus advanced states of HIV disease. *J Acquir Immune Defic Syndr*. 2000 Dec 1;25(4):296-305.

**Tremblay CL**, Hicks JL, Sutton L, Giguel F, Flynn T, Johnston M, Sax PE, Walker BD, Hirsch MS, Rosenberg ES, D'Aquila RT. Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection. *AIDS*. 2003 May 2;17(7):1086-9.

**Tural C**, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. *AIDS*. 2002;16:209-218.

US Dept of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC: US Dept of Health and Human Services; February 4, 2002. Published at: <http://hivatis.org/trtgdlns.html>.

**Vento S**, Di Perri G, Garofano T, Concia E, Bassetti D.  
Pneumocystis carinii pneumonia during primary HIV-1 infection.  
Lancet. 1993 Jul 3;342(8862):24-5.

**Vidal C**, Arnedo M, Garcia F, Mestre G, Plana M, Cruceta A, Capon A, Gallart T, Miro JM, Pumarola T, Gatell JM.  
Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine. Antivir Ther. 2002 Dec;7(4):283-7.

**Wain-Hobson S**.  
HIV genome variability in vivo. AIDS. 1989;3 Suppl 1:S13-8. Review.

**Wain-Hobson S**.  
Human immunodeficiency virus type 1 quasispecies in vivo and ex vivo.  
Curr Top Microbiol Immunol. 1992;176:181-93. Review.

**Wain-Hobson S**.  
The fastest genome evolution ever described: HIV variation in situ.  
Curr Opin Genet Dev. 1993 Dec;3(6):878-83.

**Wain-Hobson S**.  
Running the gamut of retroviral variation.  
Trends Microbiol. 1996 Apr;4(4):135-41. Review.

**Wei X**, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, et al.  
Viral dynamics in human immunodeficiency virus type 1 infection.  
Nature. 1995 Jan 12;373(6510):117-22.

**Welles SL**, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumpacker CS.  
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. J Infect Dis. 1996 Oct;174(4):696-703.

**Whitcomb JM**, Kumar R, Hughes SH.  
Sequence of the circle junction of human immunodeficiency virus type 1: implications for reverse transcription and integration.  
J Virol. 1990 Oct;64(10):4903-6.

**Wildemann B**, Haas J, Ehrhart K et al. In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1 infected patients both simultaneously in plasma but also between different body compartments such as blood and CSF. Neurology 1993; 43:2659-2663

- Wolfs TF**, Zwart G, Bakker M, Goudsmit J.  
HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. *Virology*. 1992 Jul;189(1):103-10.
- Wolinsky SM**, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, Kunstman KJ, Furtado MR, Munoz JL.  
Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. *Science*. 1992 Feb 28;255(5048):1134-7.
- Wolinsky SM**, Korber BT, Neumann AU, Daniels M, Kunstman KJ, Whetsell AJ, Furtado MR, Cao Y, Ho DD, Safrit JT.  
Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. *Science*. 1996 Apr 26;272(5261):537-42.
- Wong JK**, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD.  
In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. *J Virol*. 1997 Mar;71(3):2059-71.
- Wodarz D**. Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance. *J Theor Biol*. 2001 Dec 7;213(3):447-59.
- Wong JK**, Hezareh M, Gunthard H, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. *Science* 1997; 278:1291-129
- Xiao L**, Rudolph DL, Owen SM, Spira TJ, Lal RB. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. *AIDS* 1998 Sep 10;12(13):F137
- Yagi MJ**, Chu FN, Jiang JD, Wallace J, Mason P, Liu Y, Carafa J, Bekesi JG.  
Increases in soluble CD8 antigen in plasma, and CD8+ and CD8+CD38+ cells in human immunodeficiency virus type-1 infection. *Clin Immunol Immunopathol*. 1992 May;63(2):126-34.
- Yamaguchi Y**, Gojobori T.  
Evolutionary mechanisms and population dynamics of the third variable envelope region of HIV within single hosts. *Proc Natl Acad Sci U S A*. 1997 Feb 18;94(4):1264-9.
- Yang OO**, Sarkis PT, Trocha A, Kalams SA, Johnson RP, Walker BD. Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL. *J Immunol*. 2003 Oct 1;171(7):3718-24.
- Yokomaku Y**, Miura H, Tomiyama H, Kawana-Tachikawa A, Takiguchi M, Kojima A, Nagai Y, Iwamoto A, Matsuda Z, Ariyoshi K. Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. *J Virol*. 2004 Feb;78(3):1324-32.



- Yusa K**, Kavlick MF, Mitsuya H. HIV-1 acquires resistance to multiple classes of antiviral drugs through recombination. 4th Conference on Retroviruses and Opportunistic Infections. Whashington DC (USA) 1997
- Yusim K**, Kesmir C, Gaschen B, Addo MM, Altfeld M, Brunak S, Chigaev A, Detours V, Korber BT. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. *J Virol*. 2002 Sep;76(17):8757-68.
- Yuste E**, Lopez-Galindez C, Domingo E.  
Unusual distribution of mutations associated with serial bottleneck passages of human immunodeficiency virus type 1. *J Virol*. 2000 Oct;74(20):9546-52.
- Xiao L**, Rudolph DL, Owen SM, Spira TJ, Lal RB.  
Adaptation to promiscuous usage of CC and CXCR4-chemokine coreceptors in vivo correlates with HIV-1 disease progression. *AIDS*. 1998 Sep 10;12(13):F137-43.
- Zack JA**, Cann AJ, Lugo JP, Chen IS.  
HIV-1 production from infected peripheral blood T cells after HTLV-I induced mitogenic stimulation. *Science*. 1988 May 20;240(4855):1026-9
- Zack JA**, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS.  
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. *Cell*. 1990 Apr 20;61(2):213-22.
- Zhang L**, He T, Huang Y, Chen Z, Guo Y, Wu S, Kunstman KJ, Brown RC, Phair JP, Neumann AU, Ho DD, Wolinsky SM.  
Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. *J Virol*. 1998 Nov;72(11):9307-12
- Zhang L**, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD.  
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. *N Engl J Med*. 1999 May 27;340(21):1605-13.
- Zhang L**, Chung C, Hu BS, He T, Guo Y, Kim AJ, Skulsky E, Jin X, Hurley A, Ramratnam B, Markowitz M, Ho DD.  
Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. *J Clin Invest*. 2000 Oct;106(7):839-45.
- Zhang YM**, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. *J Virol* 1997; 71:6662-6670
- Zhu T**, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD.  
Genotypic and phenotypic characterization of HIV-1 patients with primary infection. *Science*. 1993 Aug 27;261(5125):1179-81.
- Zhu T**, Wang N, Carr A, Nam DS, Moor-Jankowski R, Cooper DA, Ho DD  
Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. *J Virol*. 1996 May;70(5):3098-107.

